Published in J Clin Invest on August 25, 2010
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92
The cell-cycle state of stem cells determines cell fate propensity. Cell (2013) 3.50
Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci (2012) 3.28
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol (2011) 2.74
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol (2012) 2.50
Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell (2014) 2.43
Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature (2014) 2.23
Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 2.20
Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature (2011) 2.03
Metagenomics and personalized medicine. Cell (2011) 2.00
Exome sequencing and analysis of induced pluripotent stem cells identify the cilia-related gene male germ cell-associated kinase (MAK) as a cause of retinitis pigmentosa. Proc Natl Acad Sci U S A (2011) 1.87
Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 1.78
Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med (2012) 1.75
Reprogramming cellular identity for regenerative medicine. Cell (2012) 1.71
Present state and future perspectives of using pluripotent stem cells in toxicology research. Arch Toxicol (2011) 1.69
In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med (2011) 1.66
Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun (2015) 1.66
Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology (2012) 1.64
A blueprint for engineering cell fate: current technologies to reprogram cell identity. Cell Res (2013) 1.50
Lung regeneration: mechanisms, applications and emerging stem cell populations. Nat Med (2014) 1.48
Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc (2013) 1.44
In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem (2011) 1.43
Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell (2013) 1.39
Genome editing of human pluripotent stem cells to generate human cellular disease models. Dis Model Mech (2013) 1.37
Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology (2013) 1.34
Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv (2014) 1.33
Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol (2015) 1.31
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology (2012) 1.25
Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol (2016) 1.24
Cell therapies for liver diseases. Liver Transpl (2012) 1.24
Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology (2012) 1.21
Induced pluripotent stem cells for modelling human diseases. Philos Trans R Soc Lond B Biol Sci (2011) 1.17
Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci (2010) 1.14
Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century. Stem Cells Int (2015) 1.12
A sensitive green fluorescent protein biomarker of N-glycosylation site occupancy. FASEB J (2012) 1.09
Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol (2012) 1.09
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A (2014) 1.07
Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome. J Biol Chem (2010) 1.07
Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Transl Med (2013) 1.06
Generation of multipotent foregut stem cells from human pluripotent stem cells. Stem Cell Reports (2013) 1.05
Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells. Diabetologia (2012) 1.04
Structural and quantitative evidence for dynamic glycome shift on production of induced pluripotent stem cells. Mol Cell Proteomics (2012) 1.04
New lessons learned from disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev (2012) 1.04
Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J Hepatol (2014) 1.03
Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. PLoS One (2014) 1.01
Pharmacogenomics of adverse drug reactions. Genome Med (2013) 1.00
Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol (2015) 1.00
Pluripotent stem cell-based cancer therapy: promise and challenges. Sci Transl Med (2012) 0.99
Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays (2012) 0.98
Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol (2013) 0.98
Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery. Exp Mol Med (2012) 0.96
Recombinant Laminins Drive the Differentiation and Self-Organization of hESC-Derived Hepatocytes. Stem Cell Reports (2015) 0.95
Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells. Cell Cycle (2011) 0.93
Cellular therapy for liver disease. Mayo Clin Proc (2014) 0.93
Interaction of Salmonella enterica Serovar Typhimurium with Intestinal Organoids Derived from Human Induced Pluripotent Stem Cells. Infect Immun (2015) 0.92
Modelling familial dysautonomia in human induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci (2011) 0.92
Stem cells - biological update and cell therapy progress. Clujul Med (2015) 0.91
Human pluripotent stem cells for modelling human liver diseases and cell therapy. Curr Gene Ther (2013) 0.90
Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell Reports (2013) 0.89
New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells. Hum Gene Ther (2013) 0.89
iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery. Acta Pharmacol Sin (2013) 0.89
Thinking outside the liver: induced pluripotent stem cells for hepatic applications. World J Gastroenterol (2013) 0.88
Wilson's disease: a comprehensive review of the molecular mechanisms. Int J Mol Sci (2015) 0.87
Induced pluripotent stem cells as a next-generation biomedical interface. Lab Invest (2011) 0.87
Mutational History of a Human Cell Lineage from Somatic to Induced Pluripotent Stem Cells. PLoS Genet (2016) 0.86
Concise review: drug discovery in the age of the induced pluripotent stem cell. Stem Cells Transl Med (2014) 0.86
Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes. Lab Invest (2015) 0.86
Induced pluripotent stem cells and personalized medicine: current progress and future perspectives. Anat Cell Biol (2011) 0.86
A high-content platform to characterise human induced pluripotent stem cell lines. Methods (2015) 0.86
Niemann-Pick type C1 patient-specific induced pluripotent stem cells display disease specific hallmarks. Orphanet J Rare Dis (2013) 0.85
Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein Cell (2012) 0.85
Generation of Distal Airway Epithelium from Multipotent Human Foregut Stem Cells. Stem Cells Dev (2015) 0.85
MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity. Toxicol Sci (2014) 0.84
Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res Ther (2012) 0.84
Investigating the feasibility of scale up and automation of human induced pluripotent stem cells cultured in aggregates in feeder free conditions. J Biotechnol (2014) 0.84
Cellular and molecular basis of liver development. Compr Physiol (2013) 0.84
Development and function of human cerebral cortex neural networks from pluripotent stem cells in vitro. Development (2015) 0.84
Mapping the Cell-Surface N-Glycoproteome of Human Hepatocytes Reveals Markers for Selecting a Homogeneous Population of iPSC-Derived Hepatocytes. Stem Cell Reports (2016) 0.83
Modelling human disease with pluripotent stem cells. Curr Gene Ther (2013) 0.83
Drug-induced liver injury: the dawn of biomarkers? F1000Prime Rep (2015) 0.82
Generation of functional hepatic cells from pluripotent stem cells. J Stem Cell Res Ther (2012) 0.82
Sustained knockdown of a disease-causing gene in patient-specific induced pluripotent stem cells using lentiviral vector-based gene therapy. Stem Cells Transl Med (2013) 0.82
Modelling human channelopathies using induced pluripotent stem cells: a comprehensive review. Stem Cells Int (2013) 0.82
Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells. Stem Cell Reports (2015) 0.81
Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics (2012) 0.81
Optimized inducible shRNA and CRISPR/Cas9 platforms for in vitro studies of human development using hPSCs. Development (2016) 0.80
Derivation of Endodermal Progenitors From Pluripotent Stem Cells. J Cell Physiol (2015) 0.80
Modeling and therapy of human liver diseases using induced pluripotent stem cells: how far have we come? Hepatology (2011) 0.80
Utility of B-13 progenitor-derived hepatocytes in hepatotoxicity and genotoxicity studies. Toxicol Sci (2013) 0.80
Improvement of carbon tetrachloride-induced acute hepatic failure by transplantation of induced pluripotent stem cells without reprogramming factor c-Myc. Int J Mol Sci (2012) 0.80
Assessing the therapeutic potential of lab-made hepatocytes. Hepatology (2016) 0.80
Induced pluripotent stem cells model personalized variations in liver disease resulting from α1-antitrypsin deficiency. Hepatology (2015) 0.80
iPS cell modeling of cardiometabolic diseases. J Cardiovasc Transl Res (2012) 0.80
Characterization of type I interferon pathway during hepatic differentiation of human pluripotent stem cells and hepatitis C virus infection. Stem Cell Res (2015) 0.80
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci (2015) 0.80
Humanized murine model for HBV and HCV using human induced pluripotent stem cells. Arch Pharm Res (2012) 0.80
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (2008) 14.26
Adapting proteostasis for disease intervention. Science (2008) 13.22
Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature (2008) 12.21
Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature (2007) 11.72
Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell (2009) 8.62
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature (2007) 4.54
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A (2009) 3.43
Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell (2009) 3.42
Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology (2010) 3.16
Human hepatocyte transplantation: worldwide results. Transplantation (2006) 3.02
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem (1996) 2.19
Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem (2009) 2.19
Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency. Hepatology (2009) 2.03
Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. Stem Cells (2009) 1.96
A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A (1994) 1.91
A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency. Hepatology (2010) 1.62
The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes. J Biol Chem (2001) 1.49
Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in alpha-1-antitrypsin deficiency. Cell Death Differ (2008) 1.45
Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways. J Biol Chem (2000) 1.45
Organizational diversity among distinct glycoprotein endoplasmic reticulum-associated degradation programs. Mol Biol Cell (2002) 1.34
Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res (2006) 1.30
Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. Chest (2005) 1.24
Cell-based therapies for metabolic liver disease. Mol Genet Metab (2008) 1.08
Regulation of phosphoenolpyruvate carboxykinase (GTP) synthesis in rat liver cells. Rapid induction of specific mRNA by glucagon or cyclic AMP and permissive effect of dexamethasone. J Biol Chem (1982) 1.05
Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opin Drug Metab Toxicol (2008) 1.03
The molecular basis of glycogen storage disease type 1a: structure and function analysis of mutations in glucose-6-phosphatase. J Biol Chem (2001) 0.98
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature (2007) 11.72
Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol (2007) 9.36
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92
Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev (2009) 4.69
Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J (2004) 3.77
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58
The cell-cycle state of stem cells determines cell fate propensity. Cell (2013) 3.50
Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet (2010) 3.44
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology (2010) 3.16
The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med (2007) 2.91
A culture system using human foreskin fibroblasts as feeder cells allows production of human embryonic stem cells. Hum Reprod (2003) 2.66
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut (2010) 2.66
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. Dev Biol (2007) 2.46
Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol (2007) 2.35
Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet (2012) 2.24
Pluripotency factors regulate definitive endoderm specification through eomesodermin. Genes Dev (2011) 2.22
Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem (2009) 2.19
Early cell fate decisions of human embryonic stem cells and mouse epiblast stem cells are controlled by the same signalling pathways. PLoS One (2009) 2.18
Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med (2002) 2.11
Paneth cells as a site of origin for intestinal inflammation. Nature (2013) 2.09
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem (2005) 2.08
M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol (2009) 2.06
Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet (2002) 2.02
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. Stem Cells (2009) 1.96
Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation (2010) 1.93
A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods. Control Clin Trials (2003) 1.93
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med (2012) 1.85
Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol (2013) 1.83
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Derivation of human embryonic stem cell lines in serum replacement medium using postnatal human fibroblasts as feeder cells. Stem Cells (2005) 1.82
Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ Res (2013) 1.80
Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.79
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72
Evaluation of the stapled transanal rectal resection technique with two staplers in the treatment of obstructive defecation syndrome. J Am Coll Surg (2006) 1.67
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66
A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency. Hepatology (2010) 1.62
Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol (2012) 1.58
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab (2006) 1.57
The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation (2011) 1.57
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med (2008) 1.54
Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet (2009) 1.52
Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 1.51
Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors. Stem Cells (2011) 1.51
Liver regeneration and recanalization time course following reversible portal vein embolization. J Hepatol (2008) 1.49
Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med (2012) 1.49
Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci U S A (2010) 1.48
The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol (2010) 1.45
Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc (2013) 1.44
COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res (2011) 1.43
B-type Eph receptors and ephrins induce growth cone collapse through distinct intracellular pathways. J Neurobiol (2003) 1.43
Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med (2013) 1.41
Increased engraftment of hepatic progenitors after activation of the hepatocyte growth factor signaling pathway by protein transduction. Exp Biol Med (Maywood) (2009) 1.40
Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell (2013) 1.39
Sexual function 6 months after first delivery. Obstet Gynecol (2008) 1.39
Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology (2005) 1.38
DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res (2010) 1.36
Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol (2005) 1.36
Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med (2010) 1.36
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology (2004) 1.35
Lineage-specific promoter DNA methylation patterns segregate adult progenitor cell types. Stem Cells Dev (2010) 1.34
Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem (2004) 1.33
Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol (2010) 1.33
Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest (2010) 1.33
6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J Biol Chem (2001) 1.31
Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant (2012) 1.31
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc (2011) 1.28
Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med (2011) 1.26
Outcomes following vaginal prolapse repair and mid urethral sling (OPUS) trial--design and methods. Clin Trials (2009) 1.24
Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.23
Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax (2012) 1.23
Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur J Neurosci (2009) 1.23
Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol (2002) 1.21